Preprint Short Note Version 2 Preserved in Portico This version is not peer-reviewed

Future Considerations for the mRNA–Lipid Nanoparticle Vaccine Platform

Version 1 : Received: 17 December 2020 / Approved: 21 December 2020 / Online: 21 December 2020 (10:26:54 CET)
Version 2 : Received: 23 December 2020 / Approved: 24 December 2020 / Online: 24 December 2020 (13:51:51 CET)

A peer-reviewed article of this Preprint also exists.

Journal reference: Current Opinion in Virology 2021
DOI: 10.1016/j.coviro.2021.03.008


Vaccines based on mRNA-containing lipid nanoparticles (LNPs) pioneered by Katalin Karikó and Drew Weissman at the University of Pennsylvania are a promising new vaccine platform used by two of the leading vaccine candidates against coronavirus disease in 2019 (COVID-19). However, there are many questions regarding their mechanism of action in humans that remain unanswered. Here we consider the immunological features of LNP components and off-target effects of the mRNA, both of which could increase the risk of side effects. We suggest ways to mitigate these potential risks by harnessing dendritic cell (DC) biology.


mRNA-LNP vaccines; side effects; dendritic cells



Comments (1)

Comment 1
Received: 24 December 2020
Commenter: Botond Igyártó
Commenter's Conflict of Interests: Author
Comment: Reworded the PEG-related section and included extra references. The acknowledgment section was also updated.
+ Respond to this comment

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 1
Metrics 0

Notify me about updates to this article or when a peer-reviewed version is published.

We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.